
|
Pharmacokinetic
Interactions of Nevirapine and Methadone and Guidelines for use
of Nevirapine to Treat Injection Drug Users [Clark SM et al.
CID 2001;33:1595] The authors studied the pharmacology of
methadone in eight patients who were receiving stable daily methadone
maintenance therapy. The results showed a substantial reduction
in the mean AUC for methadone from 12,024 ng.h/mL to 5,713 ng.h/mL.
There was a 36% reduction in the mean maximum concentration of methadone,
and 6 of the 8 participants complained of methadone withdrawal symptoms
from days 8-10 onward.
Comment: Previous studies of EFV also showed that this drug
was associated with a substantial reduction in the AUC for methadone
(57%) and a significant reduction in the maximum concentration of
methadone (48%). The results with nevirapine in this study were
similar at 51% and 36%, respectively. Nevertheless, the authors
suggest that the need for increased doses of methadone are not as
significant as suggested due to "induction-detoxification."
Their recommendation is that some patients on methadone maintenance
programs will require an increase in the methadone dose, but not
by as much as the pharmacology studies suggest. The usual need is
a methadone dose increase of 16-22% at 7-10 days depending on symptoms.
posted
11/19/2001

|

|